AI assistant
GENEDRIVE PLC — Remuneration Information 2018
Jul 19, 2018
7668_dirs_2018-07-19_252b54e4-83c2-4617-b9c4-f32b727dc0b7.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0927V
Genedrive PLC
19 July 2018
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it on 17 July 2018 share options ("Options") were granted to certain of its directors to acquire a total of 486,306 ordinary shares of 1.5p each in the capital of the Company under the Company's 2017 Share Option Scheme.
The Options have been granted with an exercise price equal to the closing price on the day before grant and vest after a period of three years if certain performance criteria are met. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
1. David Budd
2. Matthew Fowler
2.
Reason for the notification
a.
Position/status
1. CEO
2. CFO
a.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
genedrive plc
b.
LEI
213800ZYODIRZ87Y4K14
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type
of instrument
Identification code
Options over ordinary shares of 1.5 pence each
b.
Nature of the transaction
Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 5 December 2017.
c.
Price(s) and volume(s)
| Price(s) | Option price(s) | Volume(s) |
| David Budd | 30.5p | 222,260 |
| Matthew Fowler | 30.5p | 264,046 |
d.
Aggregated information
· Aggregated volume
· Price
N/A
e.
Date of the transaction
2018-17-07; UTC time
f.
Place of the transaction
Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options
For further details please contact:
| genedrive plc | +44 (0)161 989 0245 |
| David Budd: CEO | |
| Matthew Fowler: CFO | |
| Peel Hunt LLP | +44 (0)207 418 8900 |
| James Steel | |
| Oliver Jackson | |
| Stanhope Capital Ltd | +44(0)203 815 8880 |
| Patrick Claridge | |
| Consilium Strategic Communications | +44 (0)203 709 5700 |
| Chris Gardner | |
| Matthew Neal | |
| Laura Thornton | |
| [email protected] |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHEANXPFFDPEFF